Base de dados : MEDLINE
Pesquisa : C12.777.934.363 [Categoria DeCS]
Referências encontradas : 3698 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 370 ir para página                         

  1 / 3698 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28458353
[Au] Autor:Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
[Ad] Endereço:Tsukuba Research Center, Drug Discovery Research, Astellas Pharma Inc.
[Ti] Título:The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
[So] Source:Biol Pharm Bull;40(5):675-680, 2017.
[Is] ISSN:1347-5215
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Sodium glucose cotransporter 2 (SGLT2) inhibitors improve hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion. In addition to their antihyperglycemic effect, SGLT2 inhibitors also reduce body weight and fat mass in obese and overweight patients with T2DM. However, whether or not SGLT2 inhibitors similarly affect body composition of non-obese patients with T2DM remains unclear. In this study, we investigated the effect of the SGLT2 inhibitor ipragliflozin on body composition in a Goto-Kakizaki (GK) rat model of non-obese T2DM. GK rats were treated with ipragliflozin once daily for 9 weeks, starting at 23 weeks of age. Body composition was then analyzed using dual-energy X-ray absorptiometry. Treatment with ipragliflozin increased urinary glucose excretion, reduced hemoglobin A1c (HbA1c) levels and suppressed body weight gain as the dose increased. Body composition analysis revealed that body fat mass was lower in the ipragliflozin-treated groups than in the control group, while lean body mass and bone mineral contents were comparable between groups. Thus, an SGLT2 inhibitor ipragliflozin was found to promote preferential loss of fat mass in a rat model of non-obese T2DM. Ipragliflozin might also promote preferential loss of fat in non-obese patients with T2DM.
[Mh] Termos MeSH primário: Tecido Adiposo/efeitos dos fármacos
Diabetes Mellitus Tipo 2/tratamento farmacológico
Glucosídeos/farmacologia
Hipoglicemiantes/farmacologia
Transportador 2 de Glucose-Sódio/antagonistas & inibidores
Tiofenos/farmacologia
[Mh] Termos MeSH secundário: Absorciometria de Fóton
Tecido Adiposo/patologia
Animais
Composição Corporal/efeitos dos fármacos
Diabetes Mellitus Tipo 2/patologia
Dieta Hiperlipídica
Ingestão de Alimentos/efeitos dos fármacos
Glicosúria/metabolismo
Masculino
Ratos
Ratos Wistar
Perda de Peso/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucosides); 0 (Hypoglycemic Agents); 0 (Sglt2 protein, rat); 0 (Sodium-Glucose Transporter 2); 0 (Thiophenes); 3N2N8OOR7X (ipragliflozin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.1248/bpb.b16-00964


  2 / 3698 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28928119
[Au] Autor:Jackson EK; Mi Z
[Ad] Endereço:Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania edj@pitt.edu.
[Ti] Título:8-Aminoguanosine Exerts Diuretic, Natriuretic, and Glucosuric Activity via Conversion to 8-Aminoguanine, Yet Has Direct Antikaliuretic Effects.
[So] Source:J Pharmacol Exp Ther;363(3):358-366, 2017 Dec.
[Is] ISSN:1521-0103
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:8-Aminoguanosine induces diuresis, natriuresis, glucosuria, and antikaliuresis. These effects could be mediated via 8-aminoguanosine's metabolism to 8-aminoguanine. In this study, we tested this hypothesis in anesthetized rats. First, we demonstrated that at 55- to 85-minutes post-i.v. administration, 8-aminoguanosine and 8-aminoguanine (33.5 mol/kg) significantly increased urine volume [ml/30 min: 8-aminoguanosine from 0.3 ± 0.1 to 0.9 ± 0.1 (mean ± S.E.M.; = 7); 8-aminoguanine from 0.3 ± 0.1 to 1.5 ± 0.2 ( = 8)], sodium excretion ( mol/30 min: 8-aminoguanosine from 12 ± 5 to 109 ± 21; 8-aminoguanine from 18 ± 8 to 216 ± 31), and glucose excretion ( g/30 min: 8-aminoguanosine from 18 ± 3 to 159 ± 41; 8-aminoguanine from 17 ± 3 to 298 ± 65). Both compounds significantly decreased potassium excretion ( mol/30 min: 8-aminoguanosine from 62 ± 7 to 39 ± 9; 8-aminoguanine from 61 ± 10 to 34 ± 6). Next, we administered 8-aminoguanosine and 8-aminoguanine i.v. (33.5 mol/kg) and measured renal interstitial (microdialysis probes) 8-aminoguanosine and 8-aminoguanine. The i.v. administration of 8-aminoguanosine and 8-aminoguanine similarly increased renal medullary interstitial levels of 8-aminoguanine [nanograms per milliliter; 8-aminoguanosine from 4 ± 1 to 1025 ± 393 ( = 6), and 8-aminoguanine from 2 ± 1 to 1069 ± 407 ( = 6)]. Finally, we determine the diuretic, natriuretic, glucosuric, and antikaliuretic effects of intrarenal artery infusions of 8-aminoguanosine and 8-aminoguanine (0.1, 0.3, and 1 mol/kg/min). 8-Aminoguanine increased urine volume and sodium and glucose excretion by the ipsilateral kidney, yet had only mild effects at the highest dose in the contralateral kidney. Intrarenal infusions of 8-aminoguanosine did not induce diuresis, natriuresis, or glucosuria in either the ipsilateral or contralateral kidney, yet decreased potassium excretion in the ipsilateral kidney. Together these data confirm that the diuretic, natriuretic, and glucosuric effects of 8-aminoguanosine are not direct, but require metabolism to 8-aminoguanine. However, 8-aminoguanosine has direct antikaliuretic effects.
[Mh] Termos MeSH primário: Diuréticos/farmacologia
Glicosúria/urina
Guanina/análogos & derivados
Guanosina/análogos & derivados
Hiperpotassemia/tratamento farmacológico
Natriuréticos/farmacologia
[Mh] Termos MeSH secundário: Animais
Diuréticos/metabolismo
Guanina/metabolismo
Guanina/farmacologia
Guanosina/metabolismo
Guanosina/farmacologia
Guanosina/uso terapêutico
Hiperpotassemia/metabolismo
Medula Renal/efeitos dos fármacos
Medula Renal/metabolismo
Masculino
Natriuréticos/metabolismo
Ratos Sprague-Dawley
Urodinâmica/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Diuretics); 0 (Natriuretic Agents); 12133JR80S (Guanosine); 28128-41-8 (8-aminoguanine); 3868-32-4 (8-aminoguanosine); 5Z93L87A1R (Guanine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171121
[Lr] Data última revisão:
171121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170921
[St] Status:MEDLINE
[do] DOI:10.1124/jpet.117.243758


  3 / 3698 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28447791
[Au] Autor:Li Y; Shi Z; Chen L; Zheng S; Li S; Xu B; Liu Z; Liu J; Deng C; Ye F
[Ad] Endereço:Haisco Pharmaceuticals Group Co. Ltd. , 136 Baili Road, Wenjiang District, Chengdu 611130, China.
[Ti] Título:Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes.
[So] Source:J Med Chem;60(10):4173-4184, 2017 May 25.
[Is] ISSN:1520-4804
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A new class of potent and highly selective SGLT2 inhibitors is disclosed. Compound 31 (HSK0935) demonstrated excellent hSGLT2 inhibition of 1.3 nM and a high hSGLT1/hSGLT2 selectivity of 843-fold. It showed robust urinary glucose excretion in Sprague-Dawley (SD) rats and affected more urinary glucose excretion in Rhesus monkeys. Finally, an efficient synthetic route has been developed featuring a ring-closing cascade reaction to incorporate a double ketal 1-methoxy-6,8-dioxabicyclo[3.2.1]octane ring system.
[Mh] Termos MeSH primário: Compostos Bicíclicos Heterocíclicos com Pontes/química
Compostos Bicíclicos Heterocíclicos com Pontes/farmacologia
Glucose/metabolismo
Hipoglicemiantes/química
Hipoglicemiantes/farmacologia
Transportador 2 de Glucose-Sódio/antagonistas & inibidores
[Mh] Termos MeSH secundário: Animais
Compostos Bicíclicos Heterocíclicos com Pontes/farmacocinética
Células CHO
Cricetulus
Diabetes Mellitus Tipo 2/tratamento farmacológico
Diabetes Mellitus Tipo 2/metabolismo
Diabetes Mellitus Tipo 2/urina
Glucose/análise
Glicosúria/induzido quimicamente
Glicosúria/metabolismo
Seres Humanos
Hipoglicemiantes/farmacocinética
Rim/efeitos dos fármacos
Rim/metabolismo
Macaca mulatta
Masculino
Camundongos Endogâmicos ICR
Ratos Sprague-Dawley
Transportador 2 de Glucose-Sódio/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bridged Bicyclo Compounds, Heterocyclic); 0 (Hypoglycemic Agents); 0 (Sodium-Glucose Transporter 2); IY9XDZ35W2 (Glucose)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170619
[Lr] Data última revisão:
170619
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jmedchem.6b01818


  4 / 3698 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28428225
[Au] Autor:Al-Jobori H; Daniele G; Cersosimo E; Triplitt C; Mehta R; Norton L; DeFronzo RA; Abdul-Ghani M
[Ad] Endereço:Texas Diabetes Institute and The University of Texas Health Science Center at San Antonio, San Antonio, TX.
[Ti] Título:Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes.
[So] Source:Diabetes;66(7):1999-2006, 2017 Jul.
[Is] ISSN:1939-327X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Renal glucose reabsorption was measured with the stepped hyperglycemic clamp in 15 subjects with type 2 diabetes mellitus (T2DM) and 15 without diabetes after 2 days and after more chronic (14 days) treatment with empagliflozin. Patients with T2DM had significantly greater maximal renal glucose transport (Tm ) compared with subjects without diabetes at baseline (459 ± 53 vs. 337 ± 25 mg/min; < 0.05). Empagliflozin treatment for 48 h reduced the Tm in both individuals with and without diabetes by 44 ± 7 and 53 ± 6%, respectively (both < 0.001). Tm was further reduced by empagliflozin in both groups on day 14 (by 65 ± 5 and 75 ± 3%, respectively). Empagliflozin reduced the plasma glucose concentration threshold for glucose spillage in the urine similarly in individuals with T2DM and without diabetes to <40 mg/dL, which is well below the normal fasting plasma glucose concentration. In summary, sodium-glucose transporter-2 inhibition with empagliflozin reduces both Tm and threshold for glucose spillage in the urine in patients with T2DM and those without diabetes.
[Mh] Termos MeSH primário: Compostos Benzidrílicos/uso terapêutico
Diabetes Mellitus Tipo 2/tratamento farmacológico
Glucose/metabolismo
Glucosídeos/uso terapêutico
Hipoglicemiantes/uso terapêutico
Rim/metabolismo
[Mh] Termos MeSH secundário: Glicemia/metabolismo
Estudos de Casos e Controles
Diabetes Mellitus Tipo 2/metabolismo
Feminino
Técnica Clamp de Glucose
Glicosúria
Seres Humanos
Cinética
Masculino
Meia-Idade
Transportador 2 de Glucose-Sódio/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Benzhydryl Compounds); 0 (Blood Glucose); 0 (Glucosides); 0 (Hypoglycemic Agents); 0 (Sodium-Glucose Transporter 2); HDC1R2M35U (empagliflozin); IY9XDZ35W2 (Glucose)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170829
[Lr] Data última revisão:
170829
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170422
[St] Status:MEDLINE
[do] DOI:10.2337/db17-0100


  5 / 3698 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28143656
[Au] Autor:Gabriel SS; Belge H; Gassama A; Debaix H; Luciani A; Fehr T; Devuyst O
[Ad] Endereço:Institute of Physiology, University of Zürich, Zürich, Switzerland; Division of Nephrology, University Hospital Zürich, Zürich, Switzerland.
[Ti] Título:Bone marrow transplantation improves proximal tubule dysfunction in a mouse model of Dent disease.
[So] Source:Kidney Int;91(4):842-855, 2017 Apr.
[Is] ISSN:1523-1755
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Dent disease is a rare X-linked tubulopathy caused by mutations in the endosomal chloride-proton exchanger (ClC-5) resulting in defective receptor-mediated endocytosis and severe proximal tubule dysfunction. Bone marrow transplantation has recently been shown to preserve kidney function in cystinosis, a lysosomal storage disease causing proximal tubule dysfunction. Here we test the effects of bone marrow transplantation in Clcn5 mice, a faithful model for Dent disease. Transplantation of wild-type bone marrow in Clcn5 mice significantly improved proximal tubule dysfunction, with decreased low-molecular-weight proteinuria, glycosuria, calciuria, and polyuria four months after transplantation, compared to Clcn5 mice transplanted with ClC-5 knockout bone marrow. Bone marrow-derived cells engrafted in the interstitium, surrounding proximal tubule cells, which showed a rescue of the apical expression of ClC-5 and megalin receptors. The improvement of proximal tubule dysfunction correlated with Clcn5 gene expression in kidneys of mice transplanted with wild-type bone marrow cells. Coculture of Clcn5 proximal tubule cells with bone marrow-derived cells confirmed rescue of ClC-5 and megalin, resulting in improved endocytosis. Nanotubular extensions between the engrafted bone marrow-derived cells and proximal tubule cells were observed in vivo and in vitro. No rescue was found when the formation of the tunneling nanotubes was prevented by actin depolymerization or when cells were physically separated by transwell inserts. Thus, bone marrow transplantation may rescue the epithelial phenotype due to an inherited endosomal defect. Direct contacts between bone marrow-derived cells and diseased tubular cells play a key role in the rescue mechanism.
[Mh] Termos MeSH primário: Transplante de Medula Óssea
Canais de Cloreto/deficiência
Doença de Dent/cirurgia
Túbulos Renais Proximais/fisiopatologia
[Mh] Termos MeSH secundário: Animais
Comunicação Celular
Células Cultivadas
Canais de Cloreto/genética
Técnicas de Cocultura
Doença de Dent/genética
Doença de Dent/metabolismo
Doença de Dent/fisiopatologia
Modelos Animais de Doenças
Endocitose
Predisposição Genética para Doença
Glicosúria/genética
Glicosúria/metabolismo
Glicosúria/fisiopatologia
Glicosúria/prevenção & controle
Hipercalciúria/genética
Hipercalciúria/metabolismo
Hipercalciúria/fisiopatologia
Hipercalciúria/prevenção & controle
Túbulos Renais Proximais/metabolismo
Túbulos Renais Proximais/patologia
Proteína-2 Relacionada a Receptor de Lipoproteína de Baixa Densidade/metabolismo
Masculino
Camundongos Endogâmicos C57BL
Camundongos Knockout
Fenótipo
Poliúria/genética
Poliúria/metabolismo
Poliúria/fisiopatologia
Poliúria/prevenção & controle
Proteinúria/genética
Proteinúria/metabolismo
Proteinúria/fisiopatologia
Proteinúria/prevenção & controle
Recuperação de Função Fisiológica
Quimeras de Transplante
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CLC-5 chloride channel); 0 (Chloride Channels); 0 (Low Density Lipoprotein Receptor-Related Protein-2); 0 (Lrp2 protein, mouse)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170202
[St] Status:MEDLINE


  6 / 3698 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28024284
[Au] Autor:Li H; Liu C; Wang D; Zhang C
[Ad] Endereço:MOE Key Laboratory of Laser Life Science & Institute of Laser Life Science, College of Biophotonics, South China Normal University, Guangzhou 510631, China.
[Ti] Título:Chemiluminescence cloth-based glucose test sensors (CCGTSs): A new class of chemiluminescence glucose sensors.
[So] Source:Biosens Bioelectron;91:268-275, 2017 May 15.
[Is] ISSN:1873-4235
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Chemiluminescence (CL) has been widely applied in many fields, but it is rarely used in a very simple, economical but effective way. In this work, for the first time, the CL cloth-based glucose test sensors (CCGTSs) are developed as a new class of CL glucose sensors, with no need for complicated, expensive device fabrication and peripheral equipment. When integrated with desirable hydrophobic barrier in the flow channel and gravity/capillary flow induced by a difference in height between the loading zone and the detection zone, a single cloth-based device can perform the whole CL process involving two steps of enzyme reactions. The wax screen-printing approach is used to fabricate ultra-cheap CCGTSs, the glucose detection involves the enzymatic oxidation of glucose to gluconic acid and H O followed by the horseradish peroxidase (HRP)-catalyzed oxidation of luminol by H O , and the emitted CL signals are heightened with p-iodophenol (PIP) and imaged using an inexpensive, portable CCD camera. Under optimized conditions, glucose can be determined over the range of 0.1-100mM, with a detection limit of 0.0948mM and an analysis time of less than 5.5min. Finally, the applicability and validity of the CCGTSs are demonstrated for the measurement of glucose in clinical urine and serum samples. Thus, the proposed sensors could provide great promise in applications in many areas, and may facilitate the achievement of point-of-care testing.
[Mh] Termos MeSH primário: Glicemia/análise
Glicosúria/urina
Dispositivos Lab-On-A-Chip
Medições Luminescentes/instrumentação
Têxteis
[Mh] Termos MeSH secundário: Desenho de Equipamento
Glucose Oxidase/química
Peroxidase do Rábano Silvestre/química
Seres Humanos
Peróxido de Hidrogênio/química
Limite de Detecção
Substâncias Luminescentes/química
Luminol/química
Testes Imediatos
Têxteis/análise
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Luminescent Agents); 5EXP385Q4F (Luminol); BBX060AN9V (Hydrogen Peroxide); EC 1.1.3.4 (Glucose Oxidase); EC 1.11.1.- (Horseradish Peroxidase)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170531
[Lr] Data última revisão:
170531
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161227
[St] Status:MEDLINE


  7 / 3698 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27981497
[Au] Autor:Tanaka H; Takano K; Iijima H; Kubo H; Maruyama N; Hashimoto T; Arakawa K; Togo M; Inagaki N; Kaku K
[Ad] Endereço:Medical Affairs Department II, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
[Ti] Título:Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.
[So] Source:Adv Ther;34(2):436-451, 2017 Feb.
[Is] ISSN:1865-8652
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Sodium glucose co-transporter 2 (SGLT2) inhibitors exhibit diuretic activity, which is a possible mechanism underlying the cardiovascular benefit of these inhibitors. However, the osmotic diuresis-induced increase in urine volume, and the risk of dehydration have been of concern with SGLT2 inhibitor treatment. This study aimed to investigate the mechanism underlying SGLT2 inhibitor canagliflozin-induced diuresis in Japanese type 2 diabetes mellitus (T2DM) patients. METHODS: Thirteen T2DM patients received a daily oral dose of 100 mg canagliflozin before breakfast for 6 days. Blood and urine samples were collected at predetermined time points. The primary endpoint was evaluation of correlations between changes from baseline in urine volume and factors that are known to affect urine volume and between actual urine volume and these factors. RESULTS: Canagliflozin transiently increased urine volume and urinary sodium excretion on Day 1 with a return to baseline levels thereafter. Canagliflozin administration increased urinary glucose excretion, which was sustained during repeated-dose administration. Plasma atrial natriuretic peptide (ANP) and N-terminal pro-b-type natriuretic peptide (NT-proBNP) levels decreased, while plasma renin activity increased. On Day 1 of treatment, changes in sodium and potassium excretion were closely correlated with changes in urine output. A post hoc multiple regression analysis showed changes in sodium excretion and water intake as factors that affected urine volume change at Day 1. Furthermore, relative to that at baseline, canagliflozin decreased blood glucose throughout the day and increased plasma total GLP-1 after breakfast. CONCLUSION: Canagliflozin induced transient sodium excretion and did not induce water intake at Day 1; hence, natriuresis rather than glucose-induced osmotic diuresis may be a major factor involved in the canagliflozin-induced transient increase in urine output. In addition, canagliflozin decreased plasma ANP and NT-proBNP levels and increased plasma renin activity, which may be a compensatory mechanism for sodium retention, leading to subsequent urine output recovery. CLINICAL TRIAL REGISTRATION: UMIN000019462. FUNDING: Mitsubishi Tanabe Pharma Corporation.
[Mh] Termos MeSH primário: Canagliflozina
Desidratação
Diabetes Mellitus Tipo 2
Glicosúria
Transportador 2 de Glucose-Sódio
[Mh] Termos MeSH secundário: Adulto
Glicemia/análise
Canagliflozina/administração & dosagem
Canagliflozina/efeitos adversos
Desidratação/induzido quimicamente
Desidratação/diagnóstico
Desidratação/metabolismo
Desidratação/prevenção & controle
Diabetes Mellitus Tipo 2/sangue
Diabetes Mellitus Tipo 2/tratamento farmacológico
Diabetes Mellitus Tipo 2/epidemiologia
Diabetes Mellitus Tipo 2/urina
Feminino
Glicosúria/induzido quimicamente
Glicosúria/diagnóstico
Seres Humanos
Hipoglicemiantes/administração & dosagem
Hipoglicemiantes/efeitos adversos
Japão/epidemiologia
Masculino
Meia-Idade
Peptídeo Natriurético Encefálico/sangue
Fragmentos de Peptídeos/sangue
Transportador 2 de Glucose-Sódio/antagonistas & inibidores
Transportador 2 de Glucose-Sódio/metabolismo
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Hypoglycemic Agents); 0 (Peptide Fragments); 0 (Sodium-Glucose Transporter 2); 0 (pro-brain natriuretic peptide (1-76)); 0SAC974Z85 (Canagliflozin); 114471-18-0 (Natriuretic Peptide, Brain)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:161217
[St] Status:MEDLINE
[do] DOI:10.1007/s12325-016-0457-8


  8 / 3698 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27816591
[Au] Autor:Zhang Z; Chen Z; Cheng F; Zhang Y; Chen L
[Ad] Endereço:Key Laboratory of Coastal Environmental Processes and Ecological Remediation, Yantai Institute of Coastal Zone Research (YIC), Chinese Academy of Sciences (CAS); Shandong Provincial Key Laboratory of Coastal Environmental Processes, YICCAS, Yantai, Shandong 264003, PR China; University of Chinese Ac
[Ti] Título:Highly sensitive on-site detection of glucose in human urine with naked eye based on enzymatic-like reaction mediated etching of gold nanorods.
[So] Source:Biosens Bioelectron;89(Pt 2):932-936, 2017 Mar 15.
[Is] ISSN:1873-4235
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Based on enzymatic-like reaction mediated etching of gold nanorods (GNRs), an ultrasensitive visual method was developed for on-site detection of urine glucose. With the catalysis of MoO , GNRs were efficiently etched by H O which was generated by glucose-glucose oxidase enzymatic reaction. The etching of GNRs lead to a blue-shift of logitudinal localized surface plasmon resonance of GNRs, accompanied by an obvious color change from blue to red. The peak-shift and the color change can be used for detection of glucose by the spectrophotometer and the naked eyes. Under optimal condition, an excellent sensitivity toward glucose is obtained with a detection limit of 0.1µM and a visual detection limit of 3µM in buffer solution. Benefiting from the high sensitivity, the successful colorimetric detection of glucose in original urine samples was achieved, which indicates the practical applicability to the on-site determination of urine glucose.
[Mh] Termos MeSH primário: Técnicas Biossensoriais
Glucose Oxidase/química
Glucose/isolamento & purificação
Glicosúria/urina
Nanopartículas Metálicas/química
[Mh] Termos MeSH secundário: Colorimetria
Glucose/química
Glicosúria/diagnóstico
Ouro/química
Seres Humanos
Peróxido de Hidrogênio/química
Nanotubos/química
Ressonância de Plasmônio de Superfície
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
7440-57-5 (Gold); BBX060AN9V (Hydrogen Peroxide); EC 1.1.3.4 (Glucose Oxidase); IY9XDZ35W2 (Glucose)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170227
[Lr] Data última revisão:
170227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161107
[St] Status:MEDLINE


  9 / 3698 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27681704
[Au] Autor:Ono Y; Ono S; Hinata T; Ito T; Yasuda H; Tanaka Y
[Ad] Endereço:Department of General Medicine, National Defense Medical College, Tokorozawa, Japan.
[Ti] Título:Usefulness of urinary glucose excretion after oral glucose tolerance testing to detect insulin secretion failure before the onset of diabetes mellitus.
[So] Source:Endocr J;64(1):75-81, 2017 Jan 30.
[Is] ISSN:1348-4540
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Sodium-glucose cotransporter 2 inhibitors are commonly used to promote urinary glucose excretion (UGE). However, it remains unclear how UGE reflects glucose metabolism in the natural history of diabetes. Thus, we retrospectively reviewed the prediabetes medical records of 64 patients who had undergone 75-g oral glucose tolerance testing (OGTT) with measurements of UGE at 0 min, 60 min, and 120 min. The mean age and glycated hemoglobin levels were 46 ± 10 years and 5.6 ± 0.3%, respectively. The median UGE (60 min + 120 min) value was 16.8 mg ([interquartile range]: [10.5-150.0 mg]). Thus, we categorized 16 patients as having high UGE (≥150.0 mg) and 48 patients as having low UGE (<150.0 mg). As compared with the low UGE group, the high UGE group exhibited a significantly lower median insulinogenic index (0.23 [0.12-0.35] vs. 0.56 [0.31-1.06], p = 0.001) and homeostasis model assessment of ß-cell function value (46 [26-67] vs. 66 [41-85], p = 0.028). The log-transformed insulinogenic index exhibited a significant inverse association with log-transformed UGE (60 min + 120 min) (r = -0.50, p < 0.001). The association between higher UGE and lower insulinogenic index was also observed in a subgroup analysis of patients with plasma glucose levels of ≥160 mg/dL during the OGTT. Therefore, UGE measurements after OGTT may provide a useful clinical marker for detecting insulin secretion failure and advancing preventive and therapeutic interventions among populations with a high risk of developing diabetes.
[Mh] Termos MeSH primário: Glucose/análise
Glicosúria/diagnóstico
Glicosúria/urina
Estado Pré-Diabético/diagnóstico
Estado Pré-Diabético/urina
[Mh] Termos MeSH secundário: Adulto
Estudos Transversais
Feminino
Teste de Tolerância a Glucose
Seres Humanos
Insulina/secreção
Masculino
Meia-Idade
Estado Pré-Diabético/sangue
Valor Preditivo dos Testes
Estudos Retrospectivos
Urinálise
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Insulin); IY9XDZ35W2 (Glucose)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170407
[Lr] Data última revisão:
170407
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160930
[St] Status:MEDLINE
[do] DOI:10.1507/endocrj.EJ16-0289


  10 / 3698 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27415769
[Au] Autor:Wada J
[Ad] Endereço:Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
[Ti] Título:Salt and sugar: Bad company.
[So] Source:J Diabetes Investig;8(1):32-33, 2017 Jan.
[Is] ISSN:2040-1124
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:This report shed light to unrecognized mechanism for the hyperglycemia-induced sodium retention. The activation of PPAR?, elevation of serum adiponectin, and subsequent inhibition of SGLT2 may lead to natriuresis and glycosuria and it may be beneficial in hypertensive diabetic patients.
[Mh] Termos MeSH primário: Glucose/metabolismo
Hiperglicemia/metabolismo
Nefropatias/metabolismo
Sódio/metabolismo
[Mh] Termos MeSH secundário: Adiponectina/metabolismo
Tecido Adiposo/metabolismo
Animais
Diabetes Mellitus/metabolismo
Glicosúria/metabolismo
Seres Humanos
Hiperglicemia/complicações
Nefropatias/etiologia
Camundongos
Natriurese
Receptores Ativados por Proliferador de Peroxissomo/metabolismo
Transportador 2 de Glucose-Sódio/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adiponectin); 0 (Peroxisome Proliferator-Activated Receptors); 0 (SLC5A2 protein, human); 0 (Sodium-Glucose Transporter 2); 9NEZ333N27 (Sodium); IY9XDZ35W2 (Glucose)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160715
[St] Status:MEDLINE
[do] DOI:10.1111/jdi.12553



página 1 de 370 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde